A

Altimmune
D

ALT

3.39500
USD
0.07
(2.11%)
مفتوح الان
حجم التداول
28,093
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
425,161,000
المقالات
المزيد

العنوان: Altimmune

القطاع: Healthcare
الصناعة: Biotechnology
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.